Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Developmental Biology|September 26, 2002
Inhibition of muscle differentiation by the novel muscleblind-related protein CHCRRachel M Squillace, Dale M Chenault, Edith H WangBiochemical and Biophysical Research Communications|July 24, 2007
Expression pattern of muscleblind-like proteins differs in differentiating myoblastsKyung-Soon Lee, Rachel M Squillace, Edith H WangInternational Journal of Oncology|May 23, 2012
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer modelsRachel M Squillace, David Miller, Scott D Wardwell, et al.Plos One|July 14, 2009
Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathwayHui H Zhang, Jingxiang Huang, Katrin Düvel, et al.Molecular Cancer Therapeutics|October 6, 2011
Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer modelsRachel M Squillace, David Miller, Michelle Cookson, et al.Cancer Chemotherapy and Pharmacology|March 8, 2013
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer modelsJoseph M Gozgit, Rachel M Squillace, Matthew J Wongchenko, et al.Molecular Cancer Therapeutics|April 13, 2011
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimensVictor M Rivera, Rachel M Squillace, David Miller, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumorsLia Gore, Tanya M Trippett, Howard M Katzenstein, et al.Journal of Medicinal Chemistry|December 25, 2015
Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug DiscoveryStephan G Zech, Anna Kohlmann, Tianjun Zhou, et al.Journal of Medicinal Chemistry|January 11, 2013
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitorsAnna Kohlmann, Stephan G Zech, Feng Li, et al.Pageof 1